Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.

NCT01144338 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01144338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01144338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 18, 2010
Completion date
April 24, 2017
Enrollment
14,752 (actual)
Sites
629

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus